{"id":53643,"date":"2026-01-11T21:10:24","date_gmt":"2026-01-11T13:10:24","guid":{"rendered":"https:\/\/flcube.com\/?p=53643"},"modified":"2026-01-11T21:10:26","modified_gmt":"2026-01-11T13:10:26","slug":"merck-in-talks-to-acquire-revolution-medicines-for-28-32-billion-in-oncology-push","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53643","title":{"rendered":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push"},"content":{"rendered":"\n<p><strong>Merck Sharp &amp;\u202fDohme Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE:\u202fMRK<\/a>) is reportedly in advanced negotiations to acquire <strong>Revolution Medicines<\/strong> for <strong>USD\u202f28\u201132\u202fbillion<\/strong>, according to sources. The deal, if finalized, would be the <strong>largest healthcare transaction in at least two years<\/strong> since Pfizer\u2019s <strong>USD\u202f43\u202fbillion<\/strong> acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Merck Sharp &amp;\u202fDohme (MSD, NYSE:\u202fMRK)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Revolution Medicines<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td><strong>USD\u202f28\u201132\u202fbillion<\/strong> (discussed range)<\/td><\/tr><tr><td><strong>Indication Focus<\/strong><\/td><td>Pancreatic cancer, non\u2011small cell lung cancer (NSCLC)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibition of specific gene mutations (undisclosed targets)<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Pipeline replenishment post\u2011Keytruda patent cliff<\/td><\/tr><tr><td><strong>Market Context<\/strong><\/td><td>Largest healthcare deal since Pfizer\u2011Seagen (USD\u202f43\u202fB, 2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-company-profile-revolution-medicines\">Target Company Profile: Revolution Medicines<\/h2>\n\n\n\n<p>Pipeline:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pancreatic Cancer<\/strong>: Early\u2011stage clinical trials for <strong>most common pancreatic cancer type<\/strong> (likely pancreatic ductal adenocarcinoma), a disease with <strong>&lt;10% five\u2011year survival<\/strong> and <strong>limited treatment options<\/strong><\/li>\n\n\n\n<li><strong>NSCLC<\/strong>: Testing efficacy in patients with <strong>specific gene mutations<\/strong> (undisclosed, likely KRAS\u2011related)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: <strong>Targeted therapy<\/strong> designed to inhibit tumor growth by blocking <strong>oncogenic driver mutations<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Financial Performance<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Share Price<\/strong>: <strong>>100% increase<\/strong> over the past year, reflecting investor optimism on clinical progress<\/li>\n\n\n\n<li><strong>Market Cap<\/strong>: <strong>~USD\u202f25\u201130\u202fbillion<\/strong> (pre\u2011deal), making the acquisition <strong>highly dilutive<\/strong> but strategically justified<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-merck\">Strategic Rationale for Merck<\/h2>\n\n\n\n<p><strong>Pipeline Gap<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Keytruda<\/strong> (pembrolizumab) faces <strong>2028 patent expiry<\/strong> in US, with <strong>$25\u202fbillion<\/strong> at risk<\/li>\n\n\n\n<li><strong>Oncology Portfolio<\/strong>: Merck\u2019s early\u2011stage pipeline lacks <strong>late\u2011stage assets<\/strong> beyond Keytruda combos<\/li>\n\n\n\n<li><strong>Revolution\u2019s Value<\/strong>: <strong>First\u2011in\u2011class targeted therapies<\/strong> for <strong>pancreatic cancer<\/strong> (\u00a58\u201110\u202fbillion China market) and <strong>NSCLC<\/strong> (\u00a545\u202fbillion China market) provide <strong>10\u2011year growth runway<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Financial Synergies<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Savings<\/strong>: Acquiring vs. internal discovery <strong>saves 5\u20117 years<\/strong> and <strong>USD\u202f5\u20117\u202fbillion<\/strong> in R&amp;D spend<\/li>\n\n\n\n<li><strong>Tax Benefits<\/strong>: Potential for <strong>USD\u202f3\u20114\u202fbillion<\/strong> in goodwill amortization over 15 years<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-valuation\">Market Opportunity &amp; Valuation<\/h2>\n\n\n\n<p><strong>Pancreatic Cancer Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Incidence<\/strong>: <strong>500,000<\/strong> new cases annually (China: <strong>120,000<\/strong>; US: <strong>60,000<\/strong>)<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: <strong>$5\u20117\u202fbillion<\/strong> peak sales if Revolution\u2019s drug achieves <strong>20\u201125%<\/strong> penetration<\/li>\n<\/ul>\n\n\n\n<p><strong>NSCLC Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gene\u2011Mutation Subset<\/strong>: <strong>5\u20118%<\/strong> of NSCLC patients harbor targetable mutations \u2192 <strong>~80,000<\/strong> eligible patients globally<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: <strong>$3\u20115\u202fbillion<\/strong> peak sales<\/li>\n<\/ul>\n\n\n\n<p><strong>Combined Peak Sales<\/strong>: <strong>$8\u201112\u202fbillion<\/strong> globally by 2035, justifying <strong>$28\u201132\u202fbillion<\/strong> acquisition price at <strong>2.5\u20113x peak sales<\/strong> multiple (industry standard for oncology M&amp;A).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Recent Oncology Deal<\/th><th>Value<\/th><th>Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Pfizer<\/strong><\/td><td>Seagen (2023)<\/td><td>$43\u202fB<\/td><td>ADCs<\/td><\/tr><tr><td><strong>Merck<\/strong><\/td><td><strong>Revolution Medicines (2026)<\/strong><\/td><td><strong>$28\u201132\u202fB<\/strong><\/td><td>Targeted therapy<\/td><\/tr><tr><td><strong>Bristol\u2011Myers<\/strong><\/td><td>Turning Point (2022)<\/td><td>$4.1\u202fB<\/td><td>Precision oncology<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td>Revolution Medicines (rumored)<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Pressure<\/strong>: Merck\u2019s move preempts <strong>competitor bids<\/strong> from Roche and Novartis, both seeking <strong>precision oncology assets<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-structure-amp-timing\">Financial Structure &amp; Timing<\/h2>\n\n\n\n<p><strong>Deal Financing<\/strong>: Merck likely to use <strong>cash (60%) + debt (40%)<\/strong>, given <strong>$15\u202fbillion cash on hand<\/strong> and <strong>AA credit rating<\/strong>.<\/p>\n\n\n\n<p><strong>Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Announcement<\/strong>: Expected <strong>Q1\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Closing<\/strong>: <strong>Q3\u202f2026<\/strong> (pending regulatory approvals)<\/li>\n\n\n\n<li><strong>Integration<\/strong>: <strong>Q4\u202f2026<\/strong> (R&amp;D sites in Boston\/San Francisco retained)<\/li>\n<\/ul>\n\n\n\n<p><strong>Synergy Targets<\/strong>: <strong>USD\u202f500\u2011700\u202fmillion<\/strong> annual cost synergies by 2028 via <strong>shared clinical development infrastructure<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the potential acquisition, deal valuation, strategic rationale, and market potential of Revolution Medicines\u2019 pipeline. Actual results may differ materially due to negotiation outcomes, regulatory approvals, clinical trial risks, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2675,176,903,309],"class_list":["post-53643","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53643\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push\" \/>\n<meta property=\"og:description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53643\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T13:10:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T13:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push\",\"datePublished\":\"2026-01-11T13:10:24+00:00\",\"dateModified\":\"2026-01-11T13:10:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643\"},\"wordCount\":521,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"Pfizer\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53643#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53643\",\"name\":\"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-11T13:10:24+00:00\",\"dateModified\":\"2026-01-11T13:10:26+00:00\",\"description\":\"Merck Sharp &\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53643\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53643#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push - Insight, China&#039;s Pharmaceutical Industry","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53643","og_locale":"en_US","og_type":"article","og_title":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push","og_description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).","og_url":"https:\/\/flcube.com\/?p=53643","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T13:10:24+00:00","article_modified_time":"2026-01-11T13:10:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53643#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53643"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push","datePublished":"2026-01-11T13:10:24+00:00","dateModified":"2026-01-11T13:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53643"},"wordCount":521,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Merck Sharp &amp; Dohme","MSD","NYSE: MRK","Pfizer"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53643#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53643","url":"https:\/\/flcube.com\/?p=53643","name":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-11T13:10:24+00:00","dateModified":"2026-01-11T13:10:26+00:00","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE:\u202fMRK) is reportedly in advanced negotiations to acquire Revolution Medicines for USD\u202f28\u201132\u202fbillion, according to sources. The deal, if finalized, would be the largest healthcare transaction in at least two years since Pfizer\u2019s USD\u202f43\u202fbillion acquisition of Seagen in 2023, positioning Merck to bolster its oncology pipeline with Revolution\u2019s novel targeted therapies for pancreatic cancer and non\u2011small cell lung cancer (NSCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53643#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53643"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53643#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck in Talks to Acquire Revolution Medicines for $28\u201132 Billion in Oncology Push"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53643"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53643\/revisions"}],"predecessor-version":[{"id":53644,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53643\/revisions\/53644"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}